Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.40 |
| ▸ | PPARG | P37231 | 7/20 | 0.40 |
| ▸ | PPARD | Q03181 | 7/20 | 0.40 |
| ▸ | PPARA | Q07869 | 7/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.40 |
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TLR2 | O60603 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | FABP4 | P15090 | 2/20 | 0.40 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.40 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28956794 | 1.00 | CYP4F2 (0.42) | CYP4F2CYP4A11CES2GPR84PPARG | |
| SCHEMBL14715848 | 0.92 | CES2 (0.44) | CES2GPR84PPARGPPARDPPARA | |
| SCHEMBL513791 | 0.92 | CES2 (0.44) | CES2GPR84PPARGPPARDPPARA | |
| SCHEMBL2844700 | 0.92 | CYP4F2 (0.40) | CYP4F2CYP4A11GPR84PPARGPPARD | |
| SCHEMBL10674027 | 0.92 | CES2 (0.44) | CES2GPR84PPARGPPARDPPARA | |
| SCHEMBL14716164 | 0.92 | CES2 (0.44) | CES2GPR84PPARGPPARDPPARA | |
| SCHEMBL12196374 | 0.92 | CYP4F2 (0.40) | CYP4F2CYP4A11GPR84PPARGPPARD | |
| SCHEMBL6755330 | 0.92 | CES2 (0.44) | CES2GPR84PPARGPPARDPPARA | |
| SCHEMBL2142785 | 0.92 | CES2 (0.44) | CES2GPR84PPARGPPARDPPARA | |
| SCHEMBL14715979 | 0.92 | CES2 (0.44) | CES2GPR84PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070224213-A1 | Pharmaceutical Composition Comprising an Extract or Compounds Isolated from Elfvingia Applanata for the Prevention and the Treatment of Diabetes and Diabetic Complications | SON, DAL-HOON (CA) | 2007-09-27 | — | — | US | claimed |
| US-9861941-B2 | Modified sulfonated block copolymers and the preparation thereof | KRATON POLYMERS U.S. LLC (US) | 2018-01-09 | — | — | US | disclosed |
| EP-2731998-B1 | MODIFIED SULFONATED BLOCK COPOLYMERS AND THE PREPARATION THEREOF | KRATON POLYMERS US LLC (US) | 2016-05-18 | — | — | EP | disclosed |
| EP-2731998-A1 | MODIFIED SULFONATED BLOCK COPOLYMERS AND THE PREPARATION THEREOF | Kraton Polymers US LLC (US) | 2014-05-21 | — | — | EP | disclosed |
| WO-2013025271-A1 | MODIFIED SULFONATED BLOCK COPOLYMERS AND THE PREPARATION THEREOF | KRATON POLYMERS U.S. LLC (US) | 2013-02-21 | — | — | WO | disclosed |
| US-20130015071-A1 | MODIFIED SULFONATED BLOCK COPOLYMERS AND THE PREPARATION THEREOF | KRATON POLYMERS U.S. LLC (US) | 2013-01-17 | — | — | US | disclosed |
| EP-2539317-A2 | DIHYDROLIPOIC ACID DERIVATIVES COMPRISING NITRIC OXIDE AND THERAPEUTIC USES THEREOF | Invasc Therapeutics, Inc. (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20120041025-A1 | Dihydrolipoic Acid Derivatives Comprising Nitric Oxide and Therapeutic Uses Thereof | CARMEL BIOSCIENCES, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20110257130-A1 | Compositions and Methods for Treatment of Renin-Angiotensin Aldosterone System (RAAS)- Related Disorders | CARMEL BIOSCIENCES, INC. | 2011-10-20 | — | — | US | disclosed |
| EP-2358707-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF RENIN-ANGIOTENSIN ALDOSTERONE SYSTEM (RAAS)-RELATED DISORDERS | Invasc Therapeutic, Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2004026864-A1 | HETEROCYCLIC SUBSTITUTED PIPERAZINES FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2004-04-01 | — | — | WO | disclosed |
| US-6613914-B2 | Reacting an aromatic ketone with succinic anhydride and an alkoxide base to form an intermediate, reacting the intermediate with an alcohol to form ester, then reacting formed ester with N-methylhydroxylamine hydrochloride | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-09-02 | — | — | US | disclosed |
| US-20030045537-A1 | 4-(Phenylamino)-[1,4]dioxano[2,3-g]quinazoline derivatives and process for preparing the same | KOREAN INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2003-03-06 | — | — | US | disclosed |
| US-20020128487-A1 | Process for preparing 1, 5-diaryl-3-substituted pyrazoles | ABDEL-MAGID AHMED F (US) | 2002-09-12 | — | — | US | disclosed |
| EP-1144382-A3 | PROCESS FOR PREPARING 1,5-DIARYL-3-SUBSTITUTED PYRAZOLES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2002-09-11 | — | — | EP | disclosed |
| US-20020032336-A1 | Process for preparing 1,5-diaryl-3-substituted pyrazoles | ABDEL-MAGID AHMED F (US) | 2002-03-14 | — | — | US | disclosed |
| EP-1144382-A2 | PROCESS FOR PREPARING 1,5-DIARYL-3-SUBSTITUTED PYRAZOLES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2001009102-A2 | PROCESS FOR PREPARING 1,5-DIARYL-3-SUBSTITUTED PYRAZOLES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
| US-4935503-A | One step; using peroxydisulfate, ferrous, azide, and chloride salt | BIOMIRA, INC. (CA) | 1990-06-19 | — | — | US | disclosed |
| EP-0340780-A2 | Azidochlorination and diazidization of glycals | BIOMIRA, INC. (CA) | 1989-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045537-A1 | 4-(Phenylamino)-[1,4]dioxano[2,3-g]quinazoline derivatives and process for preparing the same | EGFR, ERBB2, ERBB4 | CYP4F2 1478/4885CYP4A11 1737/4885CES2 3832/4885 |
| US-20020032336-A1 | Process for preparing 1,5-diaryl-3-substituted pyrazoles | ADH5, ADH1C, ADH1A | CYP4F2 26/4885CYP4A11 23/4885CES2 938/4885 |
| US-20120041025-A1 | Dihydrolipoic Acid Derivatives Comprising Nitric Oxide and Therapeutic Uses Thereof | DLD, LDLR, ALOX15 | CYP4F2 1596/4885CYP4A11 605/4885CES2 2932/4885 |
| US-20070224213-A1 | Pharmaceutical Composition Comprising an Extract or Compounds Isolated from Elfvingia Applanata for the Prevention and the Treatment of Diabetes and Diabetic Complications | DPP7, DPP4, ELF3 | CYP4F2 143/4885CYP4A11 59/4885CES2 3690/4885 |
| US-20020128487-A1 | Process for preparing 1, 5-diaryl-3-substituted pyrazoles | ADH5, ADH1C, ADH1A | CYP4F2 26/4885CYP4A11 23/4885CES2 938/4885 |
| US-20110257130-A1 | Compositions and Methods for Treatment of Renin-Angiotensin Aldosterone System (RAAS)- Related Disorders | REN, ACE, AGT | CYP4F2 722/4885CYP4A11 144/4885CES2 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.